Biogen paid $41 per share — plus up to $4 in contingent value tied to SYFOVRE sales milestones — to acquire Apellis, a price that implies the real bet here is not the $689 million in 2025 product revenue already on the books but the nephrology infrastructure Apellis built around EMPAVELI. That commercial and medical apparatus now becomes the launch vehicle for felzartamab, Biogen’s anti-CD38 antibody targeting antibody-mediated rejection in kidney transplant patients, with Phase 3 data due in the first half of 2027. Biogen didn’t buy a complement franchise. It bought a sales force it couldn’t build fast enough on its own.
The strategic logic is cleaner than it first appears. SYFOVRE’s geographic atrophy indication sits in ophthalmology, a specialty Biogen has never seriously inhabited. EMPAVELI’s C3G and IC-MPGN approvals sit squarely in nephrology, exactly where felzartamab needs to land. Biogen gets two revenue-generating assets that fund the deal’s carrying costs while simultaneously seeding the specialist relationships that a de novo nephrology launch would take years to establish. The CVR structure on SYFOVRE is an admission that ophthalmic revenue projections carry real uncertainty — Apellis shareholders accepted downside risk in exchange for participation in upside that Biogen itself wasn’t willing to price in at close.
The EPS accretion promise — non-GAAP diluted, arriving in 2027, with a materially higher CAGR through decade’s end — is doing a lot of work in this announcement. Biogen’s legacy neuroscience revenue base has been under structural pressure, and Leqembi’s commercial ramp has been slower than the market expected at approval. Adding nearly $700 million in complement-drug revenue changes the near-term income statement, but the durable value creation story depends entirely on felzartamab’s Phase 3 readout. A positive AMR result converts this into a nephrology platform story; a failure reduces it to a complement asset acquisition at a premium multiple.
The single marker that determines whether this deal’s logic holds: felzartamab’s Phase 3 readout in antibody-mediated rejection, expected H1 2027. That data either validates the entire rationale for paying up to buy a nephrology salesforce ahead of schedule, or it exposes the Apellis acquisition as an expensive bridge to nowhere.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
